1. Home
  2. Labeler Index
  3. American Health Packaging
  4. 60687-249
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 9 images provide visual information about the product associated with Levetiracetam NDC 60687-249 by American Health Packaging, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

500 mg/5 mL Levetiracetam Oral Solution Cup Lid - 5 mL - Cup

500 mg/5 mL Levetiracetam Oral Solution Cup Lid - 5 mL - Cup

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - Figure 1

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - Figure 1

The given text represents the percentage of patients who were treated with a placebo and Levetiracetam. The treatment group received Levetiracetam at a dosage of either 1000 mg/day or 3000 mg/day. The percentage of patients in the placebo group is 30.6%, whereas the percentage of patients in the Levetiracetam group is not mentioned. The statement "*statistically significant versus placebo" indicates that the treatment with Levetiracetam was found to be significantly different from the placebo group in some aspects. However, further information is not available to determine the significance of the results.*

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - Figure 2

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - Figure 2

This appears to be a graph or chart showing the percentages of patients in different treatment groups, possibly for a medication study. The treatment groups include a placebo group and two different dosages of levetiracetam. The percentages may represent the proportion of patients who experienced a certain outcome or side effect. The values marked with an asterisk (*) may indicate a statistically significant difference between the treatment groups and the placebo group.*

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - Figure 3

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - Figure 3

This is a graph showing the percentage of patients in a study who experienced a statistically significant improvement with Levetiracetam at a dose of 3,000 mg/day versus a placebo. The graph displays percentages ranging from 45% to 0% with intervals of 5%. The study included 180 patients who received Levetiracetam and 104 patients who received a placebo. A percentage of 14.4% of patients on Levetiracetam had a statistically significant improvement versus placebo.*

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - Figure 4

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - Figure 4

The text represents a chart showing the percentage of patients experiencing a side effect while taking a placebo versus taking Levetiracetam. The drug Levetiracetam showed a statistically significant improvement in reducing side effects compared to the placebo. The chart includes percentages ranging from 0% to 40%.*

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - Figure 5

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - Figure 5

This is a table that shows the percentage of patients who were either given a Placebo or Levetiracetam. The two percentages shown are 31% and 19.6%, respectively. The table also states that Levetiracetam had a statistically significant effect compared to the Placebo.*

Figure 6: Responder Rate (≥50% Reduction from Baseline) In PGTC Seizure Frequency per Week in Study 7 - Figure 6

Figure 6: Responder Rate (≥50% Reduction from Baseline) In PGTC Seizure Frequency per Week in Study 7 - Figure 6

The text appears to be a table or chart with information about Lovetiracetam compared to a placebo in a study on patients. The table shows the number or percentage of patients in each group, but without context or additional information, it is not possible to provide a more detailed description or interpretation of the results.*

Levetiracetam Oral Solution Tray Label - Label

Levetiracetam Oral Solution Tray Label - Label

Levetiracetam Oral Solution USP is a prescription medication meant for institutional use only. It should be stored between 20° to 25°C (68° to 77°F) and excursions are permitted between 15" to 30°C (59° to 86°F). A medication guide should be dispensed with each patient. The given code is 8424967/1020F.*

Structural Formula - Structure

Structural Formula - Structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.